Descripción de la empresa
Zhongchao Inc. operates within the healthcare sector, specifically serving the Health Information Services industry by providing specialized information, education, and training resources to healthcare professionals in the People's Republic of China under the MDMOOC brand. The company executes its business strategy through two distinct operational segments focused on MDMOOC services and the sales of patented drugs, while also offering patient management services to its client base. In terms of market scale, Zhongchao Inc. currently holds a market capitalization of $7.46M and generates an annual revenue of $11.37M, though specific employee count data is not available in the provided financial records. These valuation metrics indicate that the company functions as a small-cap entity with a relatively modest revenue footprint, positioning it as a niche player rather than a large-scale industry dominant force within the Chinese healthcare information services landscape.
Salud financiera
The financial performance of the company reveals a complex cost structure where a trailing twelve-month revenue of $11.37M resulted in a net income loss of $6,310,153, highlighting significant operational expenses or non-operating charges that erode profitability. This negative net income is further supported by an EBITDA figure of $-5,901,042, suggesting that core business operations are currently generating a cash flow deficit before interest and taxes. Additionally, the company reported a free cash flow of $-1,112,632 over the same period, which indicates a lack of financial flexibility and an inability to generate excess cash for capital expenditures or shareholder returns from its daily operations. Profitability analysis shows a gross margin of 45.0%, which suggests the company retains a healthy portion of revenue after direct costs, yet this is offset by an operating margin of -92.0% and a profit margin of -55.5%, pointing to severe inefficiencies in controlling overhead or managing non-operating costs. Despite these operational losses, the balance sheet demonstrates a conservative stance with total cash reserves of $13.92M significantly outweighing total debt of $26,083, a disparity reinforced by a low debt-to-equity ratio of 0.12. Short-term liquidity appears robust given a current ratio of 11.11, which implies the company possesses ample current assets to cover its short-term liabilities without immediate risk of insolvency. However, the return on equity stands at -24.9% and the return on assets is -15.5%, metrics that collectively reveal that management has not yet achieved effective capital allocation or operational efficiency to generate returns on the invested capital.
Evaluación de valoración
Valuation metrics for Zhongchao Inc. present an interesting dichotomy as both the trailing P/E ratio and the forward P/E ratio are listed as N/A, a status that implies the market is currently unable to value the stock based on earnings multiples due to the absence of positive earnings or historical profitability. The price-to-book ratio is recorded at 0.30, indicating that the market is valuing the company at significantly less than the book value of its assets, which often signals undervaluation or potential underlying issues affecting asset quality. Alternative valuation measures provide further insight, with a price-to-sales ratio of 0.66 and an EV/EBITDA of 0.41, suggesting that the stock is priced at a fraction of its sales and enterprise value relative to its earnings, reflecting the market's cautious approach to a firm with negative earnings. Price action over the past year has been volatile, with the stock trading between a 52-week low of $1.44 and a 52-week high of $12.18, meaning the current share price sits at a level that is difficult to pinpoint precisely without the exact current price, but the range suggests high volatility typical of small-cap biotech or service firms. The beta value is not available (N/A), which prevents a direct comparison of the stock's price volatility relative to the broader market index, though the wide spread between the high and low implies significant price swings independent of general market movements.
Growth & Income
The growth profile of the company is characterized by a revenue decline of -23.2% year-over-year, while earnings growth is listed as N/A due to the negative net income position, making a direct comparison of earnings growth versus revenue growth mathematically impossible at this time. Since the company is not a dividend payer, with a dividend yield of N/A and a payout ratio of 0.0%, the firm does not distribute income to shareholders, instead retaining all earnings to potentially fund operations or research, although current operations are cash-flow negative. This zero payout ratio is theoretically sustainable only if the company can reverse its losses, but currently, the firm reinvests its scarce resources into maintaining its business segments rather than providing income generation. Overall, the growth and income profile presents a challenging picture for income-seeking investors, as the combination of negative revenue growth, negative earnings, and a lack of dividends indicates a company in a transition phase or facing significant structural headwinds that have not yet been resolved.